Tumor-selective E1a and E1b mutants
AssigneeThe Regents of the University of California
InventorsTony Reid, Farah Hedjran, Shantanu Kumar
Life of this patent
Estimating the term…
Abstract
Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
Claims20
A method of transfecting a cell, said method comprising contacting said cell with a recombinant adenovirus comprising an E1a regulatory sequence, wherein at least one Pea3 binding site, or functional portion thereof, is modified, and a DNA sequence inserted into an E1b-19K insertion site, wherein said insertion site is located between the start site of E1b-19K and the start site of E1b 55K.
Dependencies are inferred from the claim text.